The course to forging long-term manufacturing partnerships for gene therapies
The current adeno-associated virus (AAV) vector manufacturing landscape in 2024 is a “buyer’s market” with companies competing for clinical trial…
The current adeno-associated virus (AAV) vector manufacturing landscape in 2024 is a “buyer’s market” with companies competing for clinical trial…